Hippocampal atrophy on a brain MRI means the hippocampus—a seahorse-shaped structure deep in the brain critical for forming and storing memories—has shrunk or lost tissue volume. This shrinkage shows up as a visible reduction in the size of the hippocampus on the imaging scan, and it is not a normal finding. When a radiologist reports hippocampal atrophy, it signals that the brain tissue in this region has deteriorated, and this deterioration is often linked to cognitive changes or neurodegenerative disease.
The hippocampus plays a central role in the formation, organization, and consolidation of new memories. It is also one of the earliest brain structures vulnerable to damage in neurodegenerative diseases, particularly Alzheimer’s disease. Hippocampal atrophy appears on MRI as a reduction in the volume of the hippocampal formation, sometimes accompanied by encroachment of white matter or cerebrospinal fluid (CSF) into the hippocampal region. In some cases, researchers can detect microstructural changes—such as demyelination, iron deposition, and changes in water content within the tissue—before visible volume loss occurs.
Table of Contents
- How Radiologists Identify and Measure Hippocampal Atrophy on MRI
- Why Hippocampal Atrophy Matters for Alzheimer’s Disease and Dementia
- Hippocampal Atrophy and Mild Cognitive Impairment
- Causes and Risk Factors Behind Hippocampal Atrophy
- Specificity of Hippocampal Subfield Atrophy in Alzheimer’s Disease
- Prognostic Value and Prediction of Cognitive Outcomes
- From Detection to Clinical Decision-Making
How Radiologists Identify and Measure Hippocampal Atrophy on MRI
Radiologists identify hippocampal atrophy using two primary methods: visual assessment and volumetric measurement. In visual assessment, trained radiologists examine MRI images and subjectively rate the degree of atrophy using standardized scoring systems such as the MTA (medial temporal lobe atrophy) scale, which categorizes findings as normal, mild, moderate, or severe. The visual rating focuses on the relative size of the hippocampus compared to the enlarged ventricles (fluid-filled cavities) adjacent to it.
In volumetric analysis, specialized software measures the actual volume of the hippocampus in cubic centimeters. Normal hippocampal volumes average approximately 2.90 cm³ on the right side and 2.78 cm³ on the left side in healthy adults, though there is natural variation. When hippocampal volume falls significantly below these reference ranges, it indicates atrophy. Automated methods such as FreeSurfer and VolBrain have made it possible to detect smaller degrees of atrophy that might escape visual detection, and research shows that hippocampal grading systems can provide higher accuracy in predicting Alzheimer’s disease development than volume measurements alone.
Why Hippocampal Atrophy Matters for Alzheimer’s Disease and Dementia
Hippocampal atrophy is a well-established biomarker for Alzheimer’s disease-related neurodegeneration. The hippocampus is among the first brain regions affected by Alzheimer’s pathology, experiencing synaptic dysfunction and neuronal loss that manifests as visible shrinkage on MRI. Clinical studies have shown that hippocampal atrophy is present before dementia symptoms develop in people with memory deficits, making it a potential early warning sign.
Progressive hippocampal atrophy is strongly associated with cognitive decline and the clinical progression to dementia. A critical finding from research is that hippocampal atrophy can predict cognitive decline even when amyloid plaques and tau tangles—the hallmark Alzheimer’s pathologies—are not present. This means that hippocampal shrinkage reflects a significant pathway to cognitive impairment independent of classic Alzheimer’s pathology. Faster decline in hippocampal size correlates with more rapid cognitive decline, and patients with prominent medial temporal lobe atrophy experience significantly shorter cognitive stability intervals during treatment.
Hippocampal Atrophy and Mild Cognitive Impairment
Hippocampal atrophy can already be detected in many people with mild cognitive impairment (MCI), a condition representing an intermediate stage between normal aging and dementia. This discovery has positioned hippocampal volume assessment as a core biomarker for identifying individuals at risk of progressing to dementia. Each standard deviation increase in genetic risk for hippocampal atrophy elevates the relative hazard for developing amnestic MCI or Alzheimer’s disease by 46 percent, and individuals in the top genetic risk quartile face almost three times higher risk of conversion compared to those in the lowest quartile.
Importantly, hippocampal atrophy can also indicate preclinical Alzheimer’s disease—changes occurring before any cognitive symptoms emerge. Subjective cognitive decline, where individuals report memory concerns without objective test changes, has been linked to hippocampal atrophy in some patients. Research shows that hippocampal atrophy is present before dementia in people with memory deficits and can predict which individuals will develop dementia, suggesting that MRI screening of the hippocampus could identify candidates for early intervention.
Causes and Risk Factors Behind Hippocampal Atrophy
Age-related hippocampal atrophy results from neuronal loss and impaired neurogenesis—the birth of new neurons in the hippocampus, a process that continues throughout life. Neuroinflammation and reduced trophic support, particularly from growth factors like BDNF (brain-derived neurotrophic factor), contribute to age-related hippocampal dysfunction and shrinkage. Several modifiable and non-modifiable risk factors influence hippocampal volume loss.
Modifiable risk factors include diabetes, hypertension, chronic kidney disease, excessive alcohol consumption, depression, and hearing loss—all of which are associated with accelerated hippocampal atrophy. Conversely, protective factors include physical exercise, a healthy diet, lifelong learning, cognitive training, and environmental enrichment. Non-invasive strategies such as regular physical exercise and environmental enrichment have been demonstrated to counteract many age-induced changes in hippocampal signaling, structure, and function. Education level also appears protective; higher education correlates with better cognitive reserve and may slow hippocampal atrophy.
Specificity of Hippocampal Subfield Atrophy in Alzheimer’s Disease
The hippocampus is not a uniform structure; it contains distinct subfields including the CA1, CA2, CA3 regions, the dentate gyrus, and the subiculum, each with different cellular composition and vulnerability to disease. In Alzheimer’s disease, atrophy does not affect all subfields equally. Research shows that CA1, the dentate gyrus, and the subiculum exhibit significant volume reductions in Alzheimer’s spectrum participants compared to healthy controls, whereas CA2 and CA3 do not show the same pattern of atrophy.
This selective vulnerability provides insight into the specific pathological mechanisms of Alzheimer’s disease and helps explain why memory impairment is often the earliest and most prominent symptom. The pattern of hippocampal subfield atrophy relates directly to cognitive impairment along the Alzheimer’s disease spectrum. As Alzheimer’s pathology progresses through the brain, the pattern of atrophy in specific subfields changes, reflecting advancing neurodegeneration. This anatomical specificity means that a neuroradiologist examining hippocampal atrophy can sometimes infer the stage or severity of Alzheimer’s pathology based on which subfields show the greatest loss.
Prognostic Value and Prediction of Cognitive Outcomes
Smaller hippocampal volumes predict conversion from mild cognitive impairment to Alzheimer’s dementia, while larger hippocampal volumes predict cognitive stability or improvement. Higher atrophy scores predict more rapid cognitive decline in the months and years following the MRI scan. In patients treated with cholinesterase inhibitors (medications that temporarily slow Alzheimer’s progression), those with prominent medial temporal lobe atrophy experienced a significantly shorter cognitive benefit from the medication, suggesting that hippocampal atrophy severity influences treatment response.
Hippocampal atrophy is not limited to Alzheimer’s disease; it occurs in other neurological conditions as well. In multiple sclerosis, hippocampal atrophy correlates with deficits in verbal and visuospatial memory performance, even in early disease phases. Autoimmune encephalitis, neurosyphilis, temporal lobe epilepsy, and certain other neurological disorders can also cause hippocampal atrophy, underscoring the importance of clinical context when interpreting MRI findings.
From Detection to Clinical Decision-Making
When hippocampal atrophy is identified on an MRI, the clinical significance depends on age, symptoms, rate of change, and accompanying findings. In a cognitively normal older adult, mild hippocampal atrophy may represent normal aging, whereas the same finding in someone reporting memory problems or showing cognitive test changes points toward pathological neurodegeneration. Serial MRIs (scans repeated over months or years) allow measurement of the rate of hippocampal volume loss; faster atrophy rates are associated with worse prognosis and steeper cognitive decline trajectories.
The detection of hippocampal atrophy on MRI has clinical utility as a biomarker for disease staging, prognosis, and monitoring of neurodegeneration. Modern MRI protocols increasingly include high-resolution imaging of the medial temporal lobe structures to optimize detection of early hippocampal changes. As neuroimaging technology advances and automated volumetric analysis becomes more routine, hippocampal atrophy assessment is becoming an integrated part of evaluating cognitive disorders and tracking disease progression in dementia and other neurodegenerative conditions.
- —
